Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis

阿替唑单抗 彭布罗利珠单抗 医学 杜瓦卢马布 肿瘤科 养生 内科学 不利影响 阿维鲁单抗 免疫疗法 癌症
作者
Francesco Chierigo,Mike Wenzel,Christoph Würnschimmel,Rocco Simone Flammia,Benedikt Horlemann,Zhe Tian,Fred Saad,Felix K. H. Chun,Derya Tilki,Shahrokh F. Shariat,Michele Gallucci,Marco Borghesi,Nazareno Suardi,Carlo Terrone,Pierre I. Karakiewicz
出处
期刊:Critical Reviews in Oncology Hematology [Elsevier BV]
卷期号:169: 103534-103534 被引量:7
标识
DOI:10.1016/j.critrevonc.2021.103534
摘要

Three first line and three second-line clinical trials tested the effect of immunotherapy (IO) relative to standard chemotherapy (CT) on overall survival. However, network meta-analysis-based comparisons have not yet been presented. We addressed this void.To provide comparisons of overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), stable disease (SD), objective response rates (ORR), disease control rates (DCR) and adverse events (AEs) associated with 1st and 2nd line IO-based regimens.PubMed was searched for phase III randomized controlled trials from 2016 to 2021, including conference abstracts. We identified three first line [IMvigor130 (atezolizumab + CT vs atezolizumab vs CT), DANUBE (durvalumab vs durvalumab + tremelimumab vs CT), and KEYNOTE-361 (pembrolizumab + CT vs pembrolizumab vs CT)] and two second line [KEYNOTE-045 (pembrolizumab vs CT) and IMvigor211 (atezolizumab vs CT)] RCTs.Overall, 3255 and 1452 patients were respectively included in the first- and second-line settings. In 1st line setting, compared with CT, no IO-based regimen exhibited survival benefit. However, all exclusive IO regimens resulted in lower rates of grade 3+ AEs. In 2nd line setting, compared with CT, only pembrolizumab improved OS benefit. Conversely, atezolizumab only showed OS benefit in exploratory analyses. Compared to second-line CT, no experimental regimen (atezolizumab or pembrolizumab) exhibited statistically significant ORR benefit. Both pembrolizumab and atezolizumab resulted in lower rates of grade 3+ AEs compared to 2nd line CT.In metastatic UC, IO-based regimens do not hold a survival benefit relative to CT in 1st line setting. However, pembrolizumab holds a survival benefit in 2nd line compared to CT. Several IO-based clinical trials are ongoing and will provide more and possibly better treatment alternatives for locally advanced and metastatic UC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
小王同志发布了新的文献求助10
3秒前
罗明芳发布了新的文献求助30
6秒前
6秒前
Cold-Drink-Shop完成签到,获得积分10
7秒前
flj7038完成签到,获得积分0
8秒前
英勇含烟关注了科研通微信公众号
8秒前
自由茈完成签到,获得积分10
8秒前
wanci应助魁梧的冰菱采纳,获得10
10秒前
12秒前
tmxx发布了新的文献求助10
13秒前
rio完成签到 ,获得积分10
15秒前
隐形曼青应助ding采纳,获得10
17秒前
科研通AI5应助细心蚂蚁采纳,获得10
18秒前
9cc发布了新的文献求助10
18秒前
18秒前
19秒前
20秒前
20秒前
逃学威龙应助Koi_采纳,获得10
20秒前
健壮的半青完成签到 ,获得积分10
22秒前
高大豌豆发布了新的文献求助10
24秒前
24秒前
小朱发布了新的文献求助10
25秒前
落后的夜阑完成签到,获得积分10
26秒前
27秒前
zhui完成签到,获得积分10
27秒前
27秒前
ax完成签到,获得积分10
28秒前
huihui完成签到,获得积分10
29秒前
结实擎苍发布了新的文献求助10
30秒前
Vegeta完成签到 ,获得积分10
32秒前
是我呀小夏完成签到 ,获得积分10
32秒前
杨大夫发布了新的文献求助10
32秒前
33秒前
33秒前
汤圆完成签到,获得积分10
34秒前
carly完成签到 ,获得积分10
34秒前
wang完成签到,获得积分20
34秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
The First Nuclear Era: The Life and Times of a Technological Fixer 500
Unusual formation of 4-diazo-3-nitriminopyrazoles upon acid nitration of pyrazolo[3,4-d][1,2,3]triazoles 500
岡本唐貴自伝的回想画集 500
Distinct Aggregation Behaviors and Rheological Responses of Two Terminally Functionalized Polyisoprenes with Different Quadruple Hydrogen Bonding Motifs 450
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3671619
求助须知:如何正确求助?哪些是违规求助? 3228325
关于积分的说明 9779523
捐赠科研通 2938636
什么是DOI,文献DOI怎么找? 1610158
邀请新用户注册赠送积分活动 760547
科研通“疑难数据库(出版商)”最低求助积分说明 736093